Multifactorial analysis of radiochemical purity in high-activity 177Lu-labeled theranostics: impact of precursor source, 177Lu form, and production parameters

Abstract Background Lutetium-177 (177Lu) theranostics have revolutionized personalized cancer treatment, particularly with FDA-approved therapies like [177Lu]Lu-DOTA-TATE for neuroendocrine tumors and [177Lu]Lu-PSMA for prostate cancer. Despite growing clinical adoption, there is limited understandi...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	William Hunt, Mathew Long, Usama Kamil, Sunil Kellapatha, Wayne Noonan, Peter D. Roselt, Nathan Papa, Brittany Emmerson, Michael S. Hofman, Mohammad B. Haskali
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	SpringerOpen 2025-07-01
Saila:	EJNMMI Radiopharmacy and Chemistry
Gaiak:	Lutetium-177 theranostics Radiochemical purity High-activity production Carrier-added lutetium-177 Non-carrier-added lutetium-177 DOTATATE
Sarrera elektronikoa:	https://doi.org/10.1186/s41181-025-00372-5
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!